Published in Expert Rev Anti Infect Ther on December 14, 2010
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation. J Biol Chem (2014) 0.90
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. J Med Virol (2012) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology (2002) 1.57
Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog (2010) 1.51
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology (2011) 1.49
IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol (2012) 1.47
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis (2007) 1.40
Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol (2004) 1.24
Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One (2012) 1.23
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther (2011) 1.22
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ (2013) 1.21
The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A (2007) 1.19
Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ (2013) 1.09
Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother (2004) 1.00
Is there any value to hepatitis B virus genotype analysis? Curr Gastroenterol Rep (2012) 0.98
Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol (2004) 0.96
The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. Clin Infect Dis (2012) 0.92
The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology (2006) 0.87
Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy. Clin Endocrinol (Oxf) (2010) 0.86
The surveillance and diagnosis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2005) 0.84
A pill for HCV - myth or foreseeable future? Liver Int (2013) 0.83
Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int (2013) 0.83
Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver Int (2008) 0.79
Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals. BMC Pregnancy Childbirth (2013) 0.78
Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". J Hepatol (2015) 0.77
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int (2014) 0.77